期刊文献+

胸腺五肽纳米粒的制备及其处方优化 被引量:1

A novel bottom-up process to produce thymopentin nanoparticles and their formulation optimization
在线阅读 下载PDF
导出
摘要 目的建立制备胸腺五肽纳米粒的方法并对其处方进行优化,为制备符合要求的压力定量吸入气雾剂奠定基础。方法将胸腺五肽、卵磷脂、乳糖溶于叔丁醇-水的混合溶剂中,冷冻干燥,将冻干产物用异丙醇混悬,离心除去多余的卵磷脂以得到纯药物纳米粒。采用星点设计-效应面法对其中水、卵磷脂、胸腺五肽的用量进行优化,因胸腺五肽的含量受此处方影响不显著,所以只选取纳米粒的粒径、粒径分布为结果考察指标。结果最优处方:水∶叔丁醇、卵磷脂∶叔丁醇、胸腺五肽∶水的比例分别为0.5(mL∶mL)、213.5(mg∶mL)、17.0(mg∶mL),即水的用量1.5 mL、卵磷脂的用量640.57 mg、胸腺五肽的用量25.57 mg、叔丁醇的用量3.0 mL。按此处方制备的纳米粒粒径在150 nm左右,多分散系数为0.1以下,含量均能保持在98%以上。结论采用该方法制备胸腺五肽纳米粒,质量佳,重现性好,方法简便,具有良好的应用前景。 Objective A novel bottom-up process was developed to produce nanoparticles containing thymopentin and the formulation was optimized to produce desirable nanoparticles for development of pressed metered dose inhaler(pMDI) of thymopentin(TP-5).Methods A solution of TP-5,lecithin and lactose in tert-butyl alcohol(TBA)/water co-solvent system was freeze-dried to generate nanoparticles and residual lecithin was washed off in lyophilizate through centrifugation.Formulation parameters such as lecithin content in organic phase,water content in TBA/water co-solvent,and TP-5 content in water were optimized with the central composite design-response surface methodology.As the retained content of TP-5 in nanoparticles did not significantly vary with the above formulation parameters,only particle size and size distribution of TP-5 nanoparticles was taken as response parameters.Results The ratios of water to TBA,lecithin to TBA and TP-5 to water in the optimum formulation were separately 0.5(mL∶mL),213.5(mg∶mL),17.0(mg∶mL),by which TP-5 nanoparticles with about 150 nm of the mean particle size and 0.1 of polydispersity index(PI) and the retained content of TP-5 above 98% were gained.Conclusion The novel bottom-up process was demonstrated to produce TP-5 nanoparticles with process simplicity and convenience,good reproducibility as well as high-product quality.
出处 《广东药学院学报》 CAS 2012年第4期355-360,共6页 Academic Journal of Guangdong College of Pharmacy
关键词 胸腺五肽纳米粒 制备方法 处方优化 星点设计-效应面法 thymopentin nanoparticles bottom-up process formulation optimization central composite design-response surface methodology
  • 相关文献

参考文献21

  • 1ANTOSOVA Z, MACKOVA M, KRAL V, et al. Therapeutic application of peptides and proteins: parenteral forever? [ J ]. Trends Biotechnol,2009,27 ( 11 ) :628 - 635.
  • 2SHOYELE S A, SLOWEY A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery [J].lnt J Pharm,2006,314(1) :1 -8.
  • 3TERZANO C. Pressurized metered dose inhalers and add-on devices[ J]. Pulm Pharmacol Ther, 2001,14 ( 5 ) : 351 - 366.
  • 4LI Hao-ying, SEVILLE P C. Novel pMDI formulations for pulmonary delivery of proteins [ J 1-lnt J Pharm ,2010,385 (1/2) :73 -78.
  • 5TSAPIS N, BENNETF D, JACKSON B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery [ J ]. Proc Natl Acad Sci USA,2002,99 ( 19 ) : 12001 - 12005.
  • 6陈如大,任非,李国锋,刘思佳.紫杉醇聚氰基丙烯酸正丁酯纳米粒制备研究[J].南方医科大学学报,2010,30(4):763-766. 被引量:8
  • 7骆蓉芳,倪士峰,刘惠,吴一飞,仝瑛,赵桂仿.纳米材料的生物效应研究进展[J].西北药学杂志,2010,25(1):72-74. 被引量:5
  • 8RABINOW B E. Nanosuspensions in drug delivery [ J ]. Nat Rev Drug Discov,2004,3 ( 9 ) :785 - 796.
  • 9NYAMBURA B K, KELLAWAY I W,TAYLOR K M G. The processing of nanoparticies containing protein for suspension in hydrofluoroalkane propellants [ J ].nt J Pharm, 2009,372 ( 1/2 ) : 140 - 146.
  • 10TAN Yin-he, YANG Zhi-wen, PENG Xin-sheng,et al. A novel bottom-up process to produce nanoparticles containing protein and peptides for suspension in hydrofluoroalkane propellants [ J ]. Int J Pharm, 2011,413 (1/2) :167 - 173.

二级参考文献75

共引文献297

同被引文献27

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部